Chris Boerner: Kicking off this year’s JPM25 conference with insights from Bristol Myers Squibb’s work
Chris Boerner, Board Chair and Chief Executive Officer at Bristol Myers Squibb, shared a post on LinkedIn:
“I had the opportunity to kick off this year’s JPM25 conference with insights into the significant work Bristol Myers Squibb is doing to deliver sustained top-tier growth and long-term shareholder value. BMS is in a strong financial position, and our strategy is on track.
We have a wave of catalysts that will be reading out starting this year and throughout the next 18 to 24 months that will bring into sharper focus the fast-growing company we aim to be at the end of the decade.
The BMS team was incredibly energized to share this progress during JPM. We also engaged in many conversations on policy, business development, technology and beyond – many of which focused on Artificial Intelligence revolutionizing patient care and improving outcomes once considered unattainable.
I was also able to catch up with investors and industry peers and paid a visit to Jim Cramer for a Mad Money chat.
The week was an invaluable opportunity to hear more broadly about where the industry is and where it plans to go – and BMS is ready to be a leader along the journey.”
More posts featuring Chris Boerner.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023